Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Market Share: Generic Drugs (Japan)

This article was originally published in PharmAsia News

Executive Summary

Japanese sales of generic drugs increased 13 percent last year to 350 billion yen. Insiders say sales volume was up because of regulatory revisions made in April 2006 that make it easier for doctors to prescribe generics. Because of tighter price restrictions, however, actual sales value was down. The Ministry of Health says that about 1 percent of patients made the switch to generic drugs. The most popular generic drugs were an antibiotic made by Clarith, a Basen diabetes medication, and a cholesterol inhibitor produced by Mevalotin. Sawai Pharmaceutical Co. led the pack of generics manufacturers with 9.8 percent of the market. Experts say the company's success stems from its aggressive advertising campaigns, particularly TV commercials. Towa Pharmaceutical Co. came in second place with an 8.4 percent market share thanks to increased general practitioner and drug store sales. Taiyo Pharmaceutical Industry Co. and Nichiiko Pharmaceutical Co. came in third and fourth, respectively. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC065802

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel